Odyssey Therapeutics Inc ODTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $18.12
- Day Range
- $18.49–19.65
- 52-Week Range
- $15.10–29.05
- Bid/Ask
- $18.14 / $22.99
- Shares Outstanding
- 48.06M
- Market Cap
- $913.11M
- Volume/Avg
- 325,592 / 274,000
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4,374.86
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.odysseytx.com
Valuation
|
Metric
|
ODTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.16 |
Price/Sales | 4,374.86 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ODTX
|
|---|---|
Quick Ratio | 10.98 |
Current Ratio | 11.36 |
Interest Coverage | −3,950.84 |
Quick Ratio
ODTX
Profitability
|
Metric
|
ODTX
|
|---|---|
Return on Assets (Normalized) | −40.21% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ODTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^P!F@M | LOCK|C@@R | $129B | |||
| Moderna Inc
MRNA
| LOCK|WV@FBnX | LOCK|!&h | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^CSg!# | LOCK|!s&@C | $77B | |||
| argenx SE ADR
ARGX
| LOCK|$cK%^@@ | LOCK|$XG | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|cvwF#$j | LOCK|y&> | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|B!?!Zl | LOCK|s&>Zz | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!^<>Jbhy | LOCK|&#L< | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|B#@z&h | LOCK|@G | $24B | |||
| Incyte Corp
INCY
| LOCK|!@GN$l | LOCK|d>? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|K@!d&j | LOCK|f#f | $14B |
United States